Pacific Biosciences of California Inc.

06/04/2026 | Press release | Distributed by Public on 06/04/2026 15:19

Proxy Results (Form 8-K)

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
The Company held the Annual Meeting on June 3, 2026. Of the 310,487,099 shares of the Company's common stock outstanding as of 5:00 p.m. (Pacific time) on April 6, 2026, the record date for the Annual Meeting, 203,009,375 shares were represented at the Annual Meeting, either by virtual attendance or by proxy, constituting approximately 65% of shares of common stock entitled to vote at the Annual Meeting. The four matters voted on at the Annual Meeting and the voting results with respect to each such matter are set forth below:
Proposal 1: Election of Four Class III Directors
Name of Director For Against Abstain Broker Non-Votes
William Ericson 128,010,323 8,109,601 1,111,140 65,778,311
Kathy Ordoñez 130,522,400 5,673,816 1,034,848 65,778,311
Christopher M. Smith 131,731,235 4,069,337 1,430,492 65,778,311
Chris Gibson, Ph.D. 131,899,750 4,107,270 1,224,044 65,778,311
Christian O. Henry 129,999,918 5,924,115 1,307,031 65,778,311
John F. Milligan, Ph.D. 130,471,635 5,650,906 1,108,523 65,778,311
Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal.
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm
For Against Abstain Broker Non-Votes
198,046,666 3,990,483 972,226 -
The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proposal 3: Advisory Vote on Approval of Named Executive Officer Compensation
For Against Abstain Broker Non-Votes
114,050,930 21,239,989 1,940,145 65,778,311
The stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.
Proposal 4: Approval of Amendment to the 2020 Equity Incentive Plan
For Against Abstain Broker Non-Votes
114,865,820 20,469,132 1,896,112 65,778,311
The stockholders approved the amendment to the 2020 Plan to increase the number of shares of the Company's common stock reserved thereunder.
Pacific Biosciences of California Inc. published this content on June 04, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 04, 2026 at 21:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]